Further evidence for an extraglycaemic effect of GLP‐1 receptor signalling comes from the FLOW trial (n ≈ 3500), where semaglutide significantly slowed the progression of kidney disease in patients with type 2 diabetes and high renal risk, reinforcing the hypothesis of a direct renoprotective action [19]. Here, GLP1R is linked to type 2 diabetes mellitus.